Overexpression and amplification of RAB20 have been detected in pancreatic carcinoma, colorectal adenoma, and triple-negative breast cancer and are associated with high-risk clinicopathological stages and poor survival outcomes [15,16,17]. This evidence concerns the gene RAB20 and colorectal adenoma.